Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$47.62 USD

47.62
1,462,070

-1.35 (-2.76%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y

Corcept (CORT) reports wider-than-expected loss in the first quarter of 2021, with its revenues also missing estimates.

Corcept Therapeutics (CORT) Misses Q1 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -14.29% and -18.53%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss

Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.

Jazz Pharma (JAZZ) Q1 Earnings Beat, Sales Miss, Stock Down

Jazz Pharmaceuticals (JAZZ) reports mixed first-quarter 2021 results as earnings beat estimates while sales miss the same. Shares down

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?

Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon

Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline

Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant

Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.

Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates

Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.

AMRX or CORT: Which Is the Better Value Stock Right Now?

AMRX vs. CORT: Which Stock Is the Better Value Option?

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.

Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season

Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New Strong Sell Stocks for November 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View

Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.

Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?

Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Corcept Begins Enrollment in Phase III Pancreatic Cancer Study

Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.

Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?

Is (CORT) Outperforming Other Medical Stocks This Year?